1Sylvester RJ,van dermeijden AP,Oosterlinck W,et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EORTC trial[J].Eur Urol,2006,49(3):466-467.
2Ornitz DM,Xu J,Colvin JS,et al.Receptor specificity of the fibroblast growth factor family[J].J Biol Chem,1996,271(25):15292-15297.
3AviviA,Yayon A,Givol D.A novel form of FGF receptor3 using an alternative exon in the immunoglobulin domain Ⅲ[J].FEBS Lett,1993,330(3):249-252.
4Passos-BuenomR,Wilcox WR,Jabs EW,et al.Clinical spectrum of fibroblast growth factor receptormutations[J].Hummutat,1999,14(2):115-125.
6Lacy S,Lopez-Beltran A,MacLennan GT,et al,Molecular pathogenesis of urothelial carcinoma:the clinical utility of emerging new biomarkers and futuremolecular classification of bladder cancer[J].Anal Quan Cytol Histol,2009,31(1):5-16.
7Keratin J,JohannamM,Ellen C,et al.Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations[J].Neoplasia,2008,10(1):1-7.
8Rieger-Christ KM,Mourtzinos A,Lee PJ,et al.Identification of fibroblast growth factor receptor 3mutations in urine sediment DNA samples complements cytology in bladder tumor detection[J].Cancer,2003,98(4):737-744.
10hartmann A,Moser K,Kriegmairm,et al.Frequent genetic alterations in simple urothelialhyperplasiss of the bladder in patients with papillary urothelial carcinoma(In Process Citation)[J].Am J Pathol,1999,154(3):721-727.
